MacuCLEAR secures funds to advance MC-1101 trial
MacuCLEAR, a developer of novel solutions for vascular disorders of the eye, has received over $1m in funds from current investors to complete Phase 3a human efficacy trial of its lead product, MC-1101.
MacuCLEAR has also entered into a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in the territory.
MC-1101 is a proprietary, topically administered eye drop drug for treating and stopping the progression of age-related macular degeneration (AMD) from the early-stage (Dry AMD) to the late-stage (Wet AMD) by increasing ocular blood flow in the choroidal vessels.
MacuCLEAR president and CEO Phillip G Ralston said MC-1101 is on track to becoming the first treatment for Dry AMD in both the US and the Pacific Rim.
"Its unique therapeutic approach, which targets the reduced blood flow that occurs in all AMD patients, has significant advantages over treatments currently on the market and in development," Ralston added.